• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

BioElectronics Founder and CEO Andrew J. Whelan Passes Away

by Fred Pennic 10/09/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
BioElectronics Founder and CEO Andrew J. Whelan Passes Away
Andrew J. Whelan, BioElectronics Founder & CEO

– BioElectronics founder and CEO Andrew J. Whelan has died suddenly on Monday night.


– The BioElectronics management team will continue to manage day-to-day operations until a permanent replacement can be confirmed.


Andrew J. Whelan, founder, and CEO of BioElectronics Corp. suddenly passed away in his home Monday night in Frederick, Maryland.  Mr. Whelan founded BioElectronics Corporation to bring to market a breakthrough drug-free medical device, ActiPatch Therapy. ActiPatch is an analgesic device that also reduces inflammation and speeds healing.

Since its founding, Whelan successfully earned several Food & Drug Administration clearances and medical device approvals around the world. Under Whelan’s leadership, the Company earned FDA approval for reduction of edema following blepharoplasty, for osteoarthritis of the knee, and for relief of plantar fasciitis. Most recently it has won approval on the use of ActiPatch for post-operative pain to mitigate opioid use and has submitted an FDA 510(k) application for market clearance for the broad treatment of musculoskeletal pain. BioElectronics products have won multiple awards.

Andrew J. Whelan Biography

Mr. Whelan served as the President from April 2000 – 2005. He was a seasoned business executive with a strong financial, consulting and management background.  From 1993 to April 2000, Mr. Whelan served as the President of P.A. Whelan & Company, Inc., a consulting firm owned by Mr. Whelan and his wife that specialized in the health care industry.   Mr. Whelan was also a founder of Drug Counters, Inc., a chain of managed care retail pharmacies, where he served as President and Chief Executive Officer from 1992 until 1993. Drug Counters was sold to Diagnostek, Inc. in 1994.  From 1984 until 1992, Mr. Whelan served as Chairman of the Board of Directors and President of Physicians’ Pharmaceutical Services, Inc., a public company of which he was a founder. 

The BioElectronics management team will continue to manage day-to-day operations until a permanent replacement can be confirmed.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: FDA, Medical Device, physicians

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Research Report

2026 Best in KLAS Awards: The Full List of Software & Services Winners

Most-Read

The "Platform" Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

The “Platform” Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

Analysis: Oracle Cerner’s Plans for a National EHR

Oracle May Cut 30k Jobs and Sell Cerner to Fund $156B OpenAI Deal

The $1.9B Exit: Why CommonSpirit is Insourcing Revenue Cycle and Tenet is Betting Big on Conifer AI

The $1.9B Exit: Why CommonSpirit is Insourcing Revenue Cycle and Tenet is Betting Big on Conifer AI

KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms

KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms

Beyond the Hype: New KLAS Data Validates the Financial and Clinical ROI of Ambient AI

Beyond the Hype: New KLAS Data Validates the Financial and Clinical ROI of Ambient AI

Anthropic Debuts ‘Claude for Healthcare’ and Opus 4.5 to Engineer the Future of Life Sciences

Anthropic Debuts ‘Claude for Healthcare’ and Opus 4.5 to Engineer the Future of Life Sciences

OpenAI Debuts ChatGPT Health: A ‘Digital Front Door’ That Connects Medical Records to Agentic AI

OpenAI Debuts ChatGPT Health: A ‘Digital Front Door’ That Connects Medical Records to Agentic AI

From Genes to Hackers: The Hidden Cybersecurity Risks in Life Sciences

From Genes to Hackers: The Hidden Cybersecurity Risks in Life Sciences

Utah Becomes First State to Approve AI System for Prescription Renewals

Utah Becomes First State to Approve AI System for Prescription Renewals

NYC Health + Hospitals to Acquire Maimonides in $2.2B Safety Net Overhaul

NYC Health + Hospitals to Acquire Maimonides in $2.2B Safety Net Overhaul

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |